COVID-19研究用の試薬

事例集

• RBD-His

  SDS-PAGE & Western blot Analysis:

  

  Fig.1 SDS-PAGE and Western blot analysis of RBD Protein (His tag)

  Lane M1: Protein Marker, GenScript, Cat. No. M00516
  Lane M2: Protein Marker, GenScript, Cat. No. M00521
  Lane 1: BSA (2.00 μg)
  Lane 2: RBD Protein (Reducing condition, 2.00 μg)
  Lane 3: RBD Protein (Non-reducing condition, 2.00 μg)
  Lane 4: RBD Protein (Reducing condition)
  Lane 5: RBD Protein (Non-reducing condition)
  Primary antibody: Mouse-anti-His mAb (GenScript, Cat.No. A00186)

  Purity >90%

  ELISA Results Binding against ACE2

  
• RBD-mFc

  SDS-PAGE & Western blot Analysis:

  

  Fig.1 SDS-PAGE and Western blot analysis of S-RBD (mFc-tag)

  Lane M1: Protein Marker, TaKaRa, Cat. No. 3452
  Lane M2: Protein Marker, GenScript, Cat. No. M00521
  Lane 1: Reducing condition
  Lane 2: Non-reducing condition
  Lane P: Mouse IgG1, Kappa (Sigma, Cat.No.M9269) as a positive control
  Primary antibody: MonoRab™ Mouse IgG (76F10), mAb, Rabbit (GenScript, Cat.No. Cat. V90301)

  Purity >90%

  ELISA Results Binding against ACE2

  
• Spike RBD-sc-dimer

  Spike RBD-sc-dimer

  

  

  Lane M: Merker
  Lane 1: Reducing condition
  Lane 2: Non-reducing condition

  Purity: 90% by SDS-PAGE; 98% by SEC-HPLC

  

  EC50=16.8ng/mL, measured by ELISA against AEC-2

  Lianpan Dai, Tianyi Zheng, Kun Xu, A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS.Cell.August,6,2020.
• ACE2 overexpression cell line